FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381885206> ?p ?o ?g. }

• W4381885206 abstract "Abstract Study question Is there any benefit when using MACS before PGT to increase the euploid blastocysts rate in patients with high sperm DNA fragmentation? Summary answer Euploid blastocysts rate was not improved after the use of MACS in PGT patients where the male partner has high DNA fragmentation. What is known already The presence of apoptotic markers in spermatozoa is highly correlated with the failure of assisted reproduction treatments. Under normal physiological conditions, apoptotic sperm cells with externalized phosphatidylserine (PS) residues on the plasma membrane can be recognized and efficiently eliminated in the female genital tract, preventing the fertilization of the oocyte by a spermatozoon with alterations in its DNA integrity. MACS eliminates apoptotic sperm with PS residues using magnetic microbeads conjugated with Annexin V. This technique reduces the proportion of sperm with high rates of sperm DNA fragmentation and can be used to maximize assisted reproduction technique (ART) outcomes. Study design, size, duration This retrospective cohort study included 54 PGT cycles with high sperm DNA fragmentation between March 2018 and November 2022. Among them, some cycles used MACS as a selection tool for non-apoptotic sperm. The control group consisted of cycles that did not perform MACS due to the patients' decision. We compared the euploid blastocysts, fertilisation and blastocysts formation rates. Participants/materials, setting, methods PGT cycles using their own oocytes and with high sperm DNA fragmentation were separated into two groups according to the use of MACS as a selection technique (n = 25) or not (n = 29). Both groups were comparable regarding patients' age, number of mature oocytes collected and cleavage embryo quality. Semen samples were considered with high sperm DNA fragmentation after a TUNEL test ≥ 20%. Data was compared through Chi-square test with significance set at P &lt; 0.05. Main results and the role of chance The primary outcome was the euploid blastocysts rate, while secondary outcomes included fertilisation and blastocysts formation rate. No differences between MACS and control groups were observed regarding the euploid blastocyst rate [45.3% (34 euploid blastocysts/75 total blastocysts) vs. 43.4% (63/145)] or the blastocysts formation rate [43.6% (75 total blastocysts/172 normal fertilized oocytes) vs. 28.6% (18/63)]. Fertilization rate was better in the control group [72.9% (172 fertilized oocytes/236 inseminated oocytes) vs. 80.1% (145/181)], P &lt; 0.05. Limitations, reasons for caution These results need confirmation with a bigger population size. As with any retrospective study, the potential for residual confounding factors exists. Even though no significant differences were observed in terms of blastocysts formation and euploidy, other parameters such as embryo quality or birth results should be evaluated in the future. Wider implications of the findings These data suggest that MACS in PGT cycles offers no clinical benefit to increase the euploid blastocyst rate. The use of add-ons must be well justified when introduced in the laboratories' everyday work. Trial registration number Not applicable" @default.
• W4381885206 created "2023-06-25" @default.
• W4381885206 creator A5003373053 @default.
• W4381885206 creator A5006432850 @default.
• W4381885206 creator A5006439116 @default.
• W4381885206 creator A5006616903 @default.
• W4381885206 creator A5011046902 @default.
• W4381885206 creator A5015928379 @default.
• W4381885206 creator A5019755922 @default.
• W4381885206 creator A5030313068 @default.
• W4381885206 creator A5053767220 @default.
• W4381885206 creator A5060067301 @default.
• W4381885206 creator A5064806555 @default.
• W4381885206 creator A5089176023 @default.
• W4381885206 creator A5092253023 @default.
• W4381885206 creator A5092253024 @default.
• W4381885206 date "2023-06-01" @default.
• W4381885206 modified "2023-10-18" @default.
• W4381885206 title "P-179 Euploid blastocysts rate in pre-implantation genetic testing (PGT) cycles with high levels of sperm DNA fragmentation does not improve after Magnetic Activated Cell Sorting (MACS)" @default.
• W4381885206 doi "https://doi.org/10.1093/humrep/dead093.539" @default.
• W4381885206 hasPublicationYear "2023" @default.
• W4381885206 type Work @default.
• W4381885206 citedByCount "0" @default.
• W4381885206 crossrefType "journal-article" @default.
• W4381885206 hasAuthorship W4381885206A5003373053 @default.
• W4381885206 hasAuthorship W4381885206A5006432850 @default.
• W4381885206 hasAuthorship W4381885206A5006439116 @default.
• W4381885206 hasAuthorship W4381885206A5006616903 @default.
• W4381885206 hasAuthorship W4381885206A5011046902 @default.
• W4381885206 hasAuthorship W4381885206A5015928379 @default.
• W4381885206 hasAuthorship W4381885206A5019755922 @default.
• W4381885206 hasAuthorship W4381885206A5030313068 @default.
• W4381885206 hasAuthorship W4381885206A5053767220 @default.
• W4381885206 hasAuthorship W4381885206A5060067301 @default.
• W4381885206 hasAuthorship W4381885206A5064806555 @default.
• W4381885206 hasAuthorship W4381885206A5089176023 @default.
• W4381885206 hasAuthorship W4381885206A5092253023 @default.
• W4381885206 hasAuthorship W4381885206A5092253024 @default.
• W4381885206 hasBestOaLocation W43818852061 @default.
• W4381885206 hasConcept C104317684 @default.
• W4381885206 hasConcept C143191323 @default.
• W4381885206 hasConcept C16685009 @default.
• W4381885206 hasConcept C18903297 @default.
• W4381885206 hasConcept C190283241 @default.
• W4381885206 hasConcept C191015642 @default.
• W4381885206 hasConcept C196843134 @default.
• W4381885206 hasConcept C2776632385 @default.
• W4381885206 hasConcept C2778093475 @default.
• W4381885206 hasConcept C2781087480 @default.
• W4381885206 hasConcept C31573885 @default.
• W4381885206 hasConcept C43759708 @default.
• W4381885206 hasConcept C54355233 @default.
• W4381885206 hasConcept C71924100 @default.
• W4381885206 hasConcept C86803240 @default.
• W4381885206 hasConcept C88972607 @default.
• W4381885206 hasConceptScore W4381885206C104317684 @default.
• W4381885206 hasConceptScore W4381885206C143191323 @default.
• W4381885206 hasConceptScore W4381885206C16685009 @default.
• W4381885206 hasConceptScore W4381885206C18903297 @default.
• W4381885206 hasConceptScore W4381885206C190283241 @default.
• W4381885206 hasConceptScore W4381885206C191015642 @default.
• W4381885206 hasConceptScore W4381885206C196843134 @default.
• W4381885206 hasConceptScore W4381885206C2776632385 @default.
• W4381885206 hasConceptScore W4381885206C2778093475 @default.
• W4381885206 hasConceptScore W4381885206C2781087480 @default.
• W4381885206 hasConceptScore W4381885206C31573885 @default.
• W4381885206 hasConceptScore W4381885206C43759708 @default.
• W4381885206 hasConceptScore W4381885206C54355233 @default.
• W4381885206 hasConceptScore W4381885206C71924100 @default.
• W4381885206 hasConceptScore W4381885206C86803240 @default.
• W4381885206 hasConceptScore W4381885206C88972607 @default.
• W4381885206 hasIssue "Supplement_1" @default.
• W4381885206 hasLocation W43818852061 @default.
• W4381885206 hasOpenAccess W4381885206 @default.
• W4381885206 hasPrimaryLocation W43818852061 @default.
• W4381885206 hasRelatedWork W1986731359 @default.
• W4381885206 hasRelatedWork W1990387516 @default.
• W4381885206 hasRelatedWork W2110378911 @default.
• W4381885206 hasRelatedWork W2135245026 @default.
• W4381885206 hasRelatedWork W2356359592 @default.
• W4381885206 hasRelatedWork W2362902579 @default.
• W4381885206 hasRelatedWork W2769981931 @default.
• W4381885206 hasRelatedWork W3170739578 @default.
• W4381885206 hasRelatedWork W4376453406 @default.
• W4381885206 hasRelatedWork W1995798194 @default.
• W4381885206 hasVolume "38" @default.
• W4381885206 isParatext "false" @default.
• W4381885206 isRetracted "false" @default.
• W4381885206 workType "article" @default.